Tscan Therapeutics is trading 5.1% down at $0.31 amid broad market weakness after hotter-than-expected August producer inflation increased concerns about interest rates.
- The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average are each down more than 0.5%.
- No new company-specific announcement dated September 10, 2026, was identified.
- Tscan’s September 2 reorganization remains important background, including a 75% workforce reduction and paused Phase 3 enrollment, but does not directly explain today’s move.